Transgene Cassettes Using miRNA Targets for Cell-Specific Expression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing gene therapy methods lack the ability to selectively determine transgene expression within specific cell types, leading to off-target effects and reduced safety.
Innovation Solution
The use of miRNA target sequences, such as miR-124, miR-338-3p, and miR-31, operably linked to a transgene to regulate expression, reducing unwanted expression and off-target effects by incorporating these sequences into a polynucleotide or vector.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If gene therapy incorporates transgenes into cells, then therapeutic function is provided, but off-target effects occur due to lack of cell-specific expression control
Solution Approach 1:
The patent applies local quality by making the transgene expression cell-specific through miRNA target sequences. The 3' UTR region of the transgene is modified to include specific miRNA target sequences (such as miR-124, miR-338-3p, miR-31) that are only present in certain cell types. This ensures the transgene is only expressed in cells lacking these miRNAs (e.g., cancer cells), while being silenced in normal cells that express the miRNAs, thereby eliminating off-target effects and improving safety.
Solution Approach 2:
The patent changes the molecular parameter of the transgene structure by modifying its 3' untranslated region to include specific miRNA target sequences. This parameter change enables the transgene to respond to cellular miRNA profiles, allowing selective expression in target cells while preventing expression in non-target cells, thus resolving the contradiction between providing therapeutic function and avoiding off-target effects.
2Productivity
If transgene expression is enhanced for therapeutic effect, then treatment efficacy improves, but unwanted expression in non-target cells increases
Solution Approach 1:
The patent implements local quality by differentiating transgene expression based on cellular identity through miRNA recognition. The transgene incorporates specific miRNA target sequences in its 3' UTR that create cell-type-specific expression patterns. In target cells lacking the corresponding miRNAs, the transgene is highly expressed for therapeutic effect. In non-target cells expressing the miRNAs, the transgene is silenced, preventing unwanted expression. This resolves the contradiction between achieving high expression for efficacy and preventing unwanted expression for safety.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enhances cell-specific transgene expression, improving safety and reducing off-target effects by incorporating these sequences into a polynucleotide or vector.
Implementation Method 1
a polynucleotide comprising at least one miR-124 target sequence, and/or at least one miR-338-3p target sequence, and/or at least one miR-31 target sequence, wherein the miRNA target sequences are operably linked to a transgene
Data Source
AI summary
A polynucleotide comprising at least one miR-124 target sequence, and/or at least one miR-338-3p target sequence, and/or at least one miR-31 target sequence, wherein the miRNA target sequences are operably linked to a transgene.